MA50359A - Anticorps anti-cd38 et procédés d'utilisation - Google Patents
Anticorps anti-cd38 et procédés d'utilisationInfo
- Publication number
- MA50359A MA50359A MA050359A MA50359A MA50359A MA 50359 A MA50359 A MA 50359A MA 050359 A MA050359 A MA 050359A MA 50359 A MA50359 A MA 50359A MA 50359 A MA50359 A MA 50359A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762570655P | 2017-10-10 | 2017-10-10 | |
US201762570660P | 2017-10-11 | 2017-10-11 | |
US201862676221P | 2018-05-24 | 2018-05-24 | |
EP18187186 | 2018-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA50359A true MA50359A (fr) | 2020-08-19 |
Family
ID=63963620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA050359A MA50359A (fr) | 2017-10-10 | 2018-10-09 | Anticorps anti-cd38 et procédés d'utilisation |
Country Status (17)
Country | Link |
---|---|
US (3) | US11186649B2 (fr) |
EP (2) | EP4249068A3 (fr) |
JP (3) | JP7036909B2 (fr) |
KR (1) | KR20200061402A (fr) |
CN (2) | CN117964758A (fr) |
AR (1) | AR116718A1 (fr) |
AU (1) | AU2018348093A1 (fr) |
BR (1) | BR112020007002A2 (fr) |
CA (1) | CA3078800A1 (fr) |
IL (1) | IL273871A (fr) |
MA (1) | MA50359A (fr) |
MX (1) | MX2020004129A (fr) |
PH (1) | PH12020550408A1 (fr) |
SG (1) | SG11202003212PA (fr) |
TW (2) | TWI821202B (fr) |
UY (1) | UY37928A (fr) |
WO (1) | WO2019074973A2 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
TWI622597B (zh) * | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2014110601A1 (fr) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Nouvelles protéines hétérodimères |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
ES2894304T3 (es) | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
PE20190128A1 (es) | 2016-04-13 | 2019-01-17 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes |
LT3443006T (lt) | 2016-04-13 | 2023-10-25 | Sanofi | Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai |
JP7303126B2 (ja) | 2017-06-20 | 2023-07-04 | テネオバイオ, インコーポレイテッド | 抗bcma重鎖のみ抗体 |
KR20200061402A (ko) | 2017-10-10 | 2020-06-02 | 사노피 | 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합 |
JP7332627B2 (ja) | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ,インク. | 最適化された抗tl1a抗体 |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
US11613576B2 (en) * | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
WO2020210392A1 (fr) * | 2019-04-09 | 2020-10-15 | Sanofi | Protéines de liaison trispécifiques, procédés et utilisations connexes |
WO2021003074A1 (fr) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anticorps anti-cd38 et ses procédés d'utilisation |
MX2022004942A (es) | 2019-10-24 | 2022-07-27 | Prometheus Biosciences Inc | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. |
US20210123926A1 (en) | 2019-10-25 | 2021-04-29 | Sanofi | Methods for analyzing chain mispairing in multispecific binding proteins |
CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
AU2021263448A1 (en) * | 2020-04-29 | 2022-11-24 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
UY39191A (es) * | 2020-04-29 | 2021-11-30 | Teneobio Inc | Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas |
WO2021231976A1 (fr) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3 |
KR20230166150A (ko) | 2020-08-19 | 2023-12-06 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
KR20230070259A (ko) * | 2020-09-18 | 2023-05-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd38 및/또는 cd28에 결합하는 항원 결합 분자, 및 이의 용도 |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
CN117642427A (zh) * | 2021-07-14 | 2024-03-01 | 江苏恒瑞医药股份有限公司 | 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途 |
CA3226428A1 (fr) * | 2021-08-02 | 2023-02-09 | Hangzhou Unogen Biotech, Ltd | Anticorps anti-cd38, anticorps anti-cd3 et anticorps bispecifiques, et leurs utilisations |
WO2023021477A1 (fr) * | 2021-08-20 | 2023-02-23 | Novartis Ag | Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique |
WO2023246911A1 (fr) * | 2022-06-24 | 2023-12-28 | 北京可瑞生物科技有限公司 | Molécule polypeptidique bispécifique à base de récepteur de lymphocytes t et son utilisation |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308936B1 (fr) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Hétéroconjugués d'anticorps pour tuer des cellules infectées par VIH |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
WO2005000899A2 (fr) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Molecules de liaison modifiees comprenant des peptides de connexion |
US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
NZ548990A (en) * | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
EP2551282A3 (fr) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Anticorps diriges contre CD38 pour le traitement du myelome multiple |
EP1914242A1 (fr) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
EP2050764A1 (fr) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Nouveau format d'anticorps bispécifique polyvalent |
EP3002299A1 (fr) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Immunoglobulines à deux domaines variables et leurs utilisations |
US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
LT2580243T (lt) | 2010-06-09 | 2020-01-27 | Genmab A/S | Antikūnai prieš žmogaus cd38 |
JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
TWI622597B (zh) | 2011-03-28 | 2018-05-01 | 賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
WO2012154312A1 (fr) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps neutralisants anti-vih-1 et leur utilisation |
ES2895523T3 (es) | 2011-05-17 | 2022-02-21 | Univ Rockefeller | Anticuerpos neutralizantes del virus de inmunodeficiencia humana y métodos de uso de los mismos |
CN104080805B (zh) | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
CN108676091B (zh) | 2011-12-08 | 2022-04-01 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
WO2013163427A1 (fr) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Anticorps pour traiter les infections par le vih-1 |
EP2928924A4 (fr) | 2012-12-04 | 2016-07-13 | Univ Maryland | Anticorps liant la protéine env du vih-1, protéines de fusion et leurs méthodes d'utilisation |
US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
US10487155B2 (en) * | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
EP2948475A2 (fr) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Procédés et compositions pour la modulation du systéme immunitaire |
CA2904407A1 (fr) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | Proteines de liaison specifiques a domaines variables doubles dirigees contre tnf |
SG10201909806SA (en) | 2013-11-04 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
US10961506B2 (en) | 2014-09-04 | 2021-03-30 | Stemcell Technologies Inc. | Soluble antibody complexes for T cell or NK cell activation and expansion |
AU2016210068B2 (en) | 2015-01-23 | 2021-10-28 | Sanofi | Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123 |
WO2016196740A1 (fr) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Anticorps tri-spécifiques pour traitement anti-vih |
ES2894304T3 (es) | 2015-10-25 | 2022-02-14 | Sanofi Sa | Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH |
CN105837688B (zh) * | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因,免疫毒素及其编码基因、制备方法、表达载体、应用,及宿主细胞 |
PE20190128A1 (es) * | 2016-04-13 | 2019-01-17 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes |
WO2018120842A1 (fr) | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | Molécule bifonctionnelle et son utilisation |
US10626169B2 (en) | 2017-02-17 | 2020-04-21 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
KR20200061402A (ko) | 2017-10-10 | 2020-06-02 | 사노피 | 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합 |
AU2019357467A1 (en) | 2018-10-09 | 2021-05-27 | Sanofi | Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection |
US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2018
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/ko not_active Application Discontinuation
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/fr active Pending
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/zh active Pending
- 2018-10-09 CN CN201880079045.9A patent/CN111788225A/zh active Pending
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en active Pending
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/pt unknown
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 CA CA3078800A patent/CA3078800A1/fr active Pending
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/es unknown
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/fr active Active
- 2018-10-09 MA MA050359A patent/MA50359A/fr unknown
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/ja active Active
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/fr unknown
- 2018-10-10 UY UY0001037928A patent/UY37928A/es not_active Application Discontinuation
- 2018-10-11 TW TW107135898A patent/TWI821202B/zh active
- 2018-10-11 TW TW112124284A patent/TW202342544A/zh unknown
-
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/es unknown
-
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
-
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
-
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/ja active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
-
2023
- 2023-11-14 JP JP2023193393A patent/JP2024020377A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020007002A2 (pt) | 2020-11-17 |
US20220041746A1 (en) | 2022-02-10 |
CN111788225A (zh) | 2020-10-16 |
JP2024020377A (ja) | 2024-02-14 |
EP4249068A3 (fr) | 2023-11-22 |
AR116718A1 (es) | 2021-06-09 |
KR20200061402A (ko) | 2020-06-02 |
MX2020004129A (es) | 2020-08-20 |
JP7387780B2 (ja) | 2023-11-28 |
JP2020536543A (ja) | 2020-12-17 |
RU2020115450A (ru) | 2021-11-15 |
US11186649B2 (en) | 2021-11-30 |
UY37928A (es) | 2019-05-31 |
IL273871A (en) | 2020-05-31 |
CN117964758A (zh) | 2024-05-03 |
WO2019074973A3 (fr) | 2019-06-13 |
PH12020550408A1 (en) | 2021-04-12 |
US11365261B2 (en) | 2022-06-21 |
EP3694882A2 (fr) | 2020-08-19 |
TW202342544A (zh) | 2023-11-01 |
JP2022071087A (ja) | 2022-05-13 |
WO2019074973A2 (fr) | 2019-04-18 |
EP4249068A2 (fr) | 2023-09-27 |
CA3078800A1 (fr) | 2019-04-18 |
US20190106504A1 (en) | 2019-04-11 |
SG11202003212PA (en) | 2020-05-28 |
TW201930338A (zh) | 2019-08-01 |
EP3694882B1 (fr) | 2024-06-19 |
JP7036909B2 (ja) | 2022-03-15 |
US20220275102A1 (en) | 2022-09-01 |
AU2018348093A1 (en) | 2020-05-28 |
TWI821202B (zh) | 2023-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA45671A (fr) | Anticorps antivirus zika et procédés d'utilisation | |
MA52753A (fr) | Anticorps anti-sirpa et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA43658A (fr) | Anticorps anti-ror1, anticorps bispécifiques ror1 x cd3, et leurs procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |